Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.
It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing
Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?
Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.